Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection

Muhammad Hashim; Muhammad Ahsan; Mohammad Saud Khan; Hafsa Hameed Thakur; Talha Kamran Khan; Kamran Zahoor; Sania Muzaffar; Feroza Fatima; Shamama Tu Zahra; Ammara Naeem; Mahima Gandhi; Muhammad Usama Ashraf; M. Nauman Qureshi

doi:10.18632/oncoscience.643

December 30, 2025OncoscienceOpen Access

Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection

View Full Paper

Ask AI

Bookmark

Share

Key Points

To investigate the patterns of gastrointestinal toxicity associated with targeted cancer therapies and their implications for patient safety.
Analyzed clinicopathologic data related to GI toxicity from targeted cancer therapies.
Integrated clinical history with pathology for better management.
Reviewed national surveillance data including FAERS and SEER.
Identified characteristic pathology patterns of GI toxicity related to cancer therapies.
Found that enhanced pharmacovigilance improves patient management.
Emphasized the need for collaboration between pathology and oncology for patient safety.

Implication

This analysis reveals gi toxicity patterns in targeted cancer therapies, implying a need for improved patient protection measures.

Abstract

The landscape of GI toxicity from targeted cancer therapies is expanding rapidly. Accurate recognition of characteristic pathology patterns and integration with clinical history are crucial for safe and effective management. Enhanced pharmacovigilance, pathology-oncology collaboration, and incorporation of national surveillance data (FAERS, SEER) are essential to advancing precision medicine and patient safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hashim et al. (2025) studied this question.

synapsesocial.com/papers/699010ce2ccff479cfe56f65 https://doi.org/10.18632/oncoscience.643

View Full Paper

Ask AI

Bookmark

Share

Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection

Key Points

Implication

Abstract

Discussion

Cite This Study

Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Oncoscience

Keep reading

More related papers

More from Oncoscience